NEAT1 and MALAT1 are highly expressed in saliva and nasopharyngeal swab samples of COVID-19 patients.
Ana Carolina RodriguesDouglas AdamoskiGustavo GenelhouldFelipe ZhenGuilherme Eiji YamagutoPatrícia Savio Araujo-SouzaMeri Bordignon NogueiraSonia Mara RaboniAna Claudia BonattoDaniela Fiori GradiaJaqueline Carvalho de OliveiraPublished in: Molecular oral microbiology (2021)
COVID-19, caused by the SARS-CoV-2 virus, has become a significant global public health problem, with a wide variety of clinical manifestations and disease progression outcomes. LncRNAs are key regulators of the immune response and have been associated with COVID-19 risk infection. Previous studies focused mainly on in-silico analysis of lncRNA expression in the lungs or peripheral blood cells. We evaluated the expression of lncRNAs NEAT1, MALAT1, and MIR3142 in saliva and nasopharyngeal swab from SARS-CoV-2 positive (n = 34) and negative patients (n = 46). A higher expression of the lncRNAs NEAT1 and MALAT1 (p < 0.05) were found in positive samples. NEAT1 had a higher expression mainly in saliva samples (p < 0.001), and MALAT1 was upregulated in nasopharyngeal samples (p < 0.05). Area under the ROC curve for NEAT1 in saliva was 0.8067. This study was the first to investigate the expression of lncRNAs in saliva and nasopharyngeal samples of COVID-19 patients, which gives new insights into the initial response to infection and infectivity and may provide new biomarkers for severity and targets for therapy.
Keyphrases
- sars cov
- poor prognosis
- public health
- long non coding rna
- immune response
- peripheral blood
- coronavirus disease
- respiratory syndrome coronavirus
- binding protein
- end stage renal disease
- stem cells
- adipose tissue
- toll like receptor
- network analysis
- prognostic factors
- signaling pathway
- skeletal muscle
- dendritic cells
- peritoneal dialysis
- weight loss
- insulin resistance
- mesenchymal stem cells